Arcutis Biotherapeutics (ARQT) vs Viridian Therapeutics (VRDN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Viridian Therapeutics (VRDN) has outperformed Arcutis Biotherapeutics (ARQT) over the past year, losing 1.3% versus a loss of 10.6%. Over five years, VRDN leads with a +63.7% price change compared with +58.1% for ARQT. Viridian Therapeutics is the larger company by market cap ($3.40 billion vs $3.33 billion), about 1.0 times the size.
Arcutis Biotherapeutics converts more of its revenue into profit, with a net margin of -4.3% versus -483.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | VRDN |
|---|---|---|
| Share price | $26.36 | $29.96 |
| Market cap | $3.33B | $3.40B |
| 1-day change | -2.98% | -4.71% |
| YTD return | -9.23% | -3.73% |
| 1-year return | -10.61% | -1.25% |
| 5-year return | +58.13% | +63.72% |
| P/E ratio (TTM) | 119.82 | — |
| Forward P/E | 24.09 | — |
| EPS (TTM) | $0.22 | $-3.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $70.85M |
| Revenue growth (YoY) | +91.34% | +23359.93% |
| Net income (latest FY) | $-16.14M | $-342.60M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | -512.91% |
| Net margin | -4.29% | -483.57% |
| 52-week high | $34.80 | $34.29 |
| 52-week low | $19.30 | $13.18 |
| Distance from 52-week high | -24.25% | -12.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.19% | +42.72% |
| Average volume | 2.58M | 2.14M |
| Shares outstanding | 126.46M | 113.56M |
| Employees | 354 | 252 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Arcutis Biotherapeutics is more profitable, keeping -4.3 cents of every revenue dollar as net income versus -483.6 cents for Viridian Therapeutics.
- Viridian Therapeutics grew revenue faster in its latest fiscal year (+23359.93% vs +91.34%).
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Viridian Therapeutics
VRDN stock →Viridian Therapeutics, Inc. engages in discovering, developing, and commercializing treatments for serious and rare diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 252 employees
ARQT vs VRDN FAQ
Which is bigger, Arcutis Biotherapeutics or Viridian Therapeutics?
Viridian Therapeutics (VRDN) is larger, with a market capitalization of $3.40B compared with $3.33B for Arcutis Biotherapeutics (ARQT).
Which stock has performed better over the past year, ARQT or VRDN?
VRDN returned -1.25% over the past 12 months, compared with -10.61% for ARQT (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Viridian Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.